Valeria La Pietra
Overview
Explore the profile of Valeria La Pietra including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
408
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Perrone P, Notariale R, Lettieri G, Mele L, La Pietra V, Piscopo M, et al.
Free Radic Biol Med
. 2024 Nov;
227():42-51.
PMID: 39613047
In several physiopathological processes, phosphatidylserine (PS), normally sequestered to the inner leaflet of the plasma membrane, becomes exposed to the cell surface. In erythrocytes (RBC), PS externalization is a crucial...
2.
Facen E, Assoni G, Donati G, Paladino D, Carreira A, Bonomo I, et al.
Sci Rep
. 2024 Oct;
14(1):24501.
PMID: 39424621
The RNA binding protein Human Antigen R (HuR) has been identified as a main regulator of the innate immune response and its inhibition can lead to beneficial anti-inflammatory effects. To...
3.
La Pietra V, Montalbano A
Arch Pharm (Weinheim)
. 2024 Jun;
357(8):e2400408.
PMID: 38889399
No abstract available.
4.
Saviano A, Schettino A, Iaccarino N, Mansour A, Begum J, Marigliano N, et al.
J Autoimmun
. 2024 Mar;
144:103181.
PMID: 38522129
Inflammatory bowel diseases (IBDs) are chronic intestinal disorders often characterized by a dysregulation of T cells, specifically T helper (Th) 1, 17 and T regulatory (Treg) repertoire. Increasing evidence demonstrates...
5.
Merlino F, Pecoraro A, Longobardi G, Donati G, Di Leva F, Brignola C, et al.
J Med Chem
. 2024 Jan;
67(3):1812-1824.
PMID: 38285632
Colorectal cancer (CRC) often involves wild-type p53 inactivation by MDM2 and MDM4 overexpression, promoting tumor progression and resistance to 5-fluoruracil (5-FU). Disrupting the MDM2/4 heterodimer can proficiently reactivate p53, sensitizing...
6.
Donati G, Viviano M, DAmore V, Cipriano A, Diakogiannaki I, Amato J, et al.
Arch Pharm (Weinheim)
. 2023 Dec;
357(3):e2300583.
PMID: 38110703
Immunotherapy has emerged as a game-changing approach for cancer treatment. Although monoclonal antibodies (mAbs) targeting the programmed cell death protein 1/programmed cell death protein 1 ligand 1 (PD-1/PD-L1) axis have...
7.
Donati G, DAmore V, Russomanno P, Cerofolini L, Amato J, Marzano S, et al.
Comput Struct Biotechnol J
. 2023 Jun;
21:3355-3368.
PMID: 37384351
Today it is widely recognized that the PD-1/PD-L1 axis plays a fundamental role in escaping the immune system in cancers, so that anti-PD-1/PD-L1 antibodies have been evaluated for their antitumor...
8.
Bonomo I, Assoni G, La Pietra V, Canarutto G, Facen E, Donati G, et al.
Dis Model Mech
. 2023 Mar;
16(3).
PMID: 36912171
Lipopolysaccharide (LPS) exposure to macrophages induces an inflammatory response, which is regulated at the transcriptional and post-transcriptional levels. HuR (ELAVL1) is an RNA-binding protein that regulates cytokines and chemokines transcripts...
9.
Nuti E, La Pietra V, Daniele S, Cuffaro D, Ciccone L, Giacomelli C, et al.
Pharmaceuticals (Basel)
. 2022 Nov;
15(11).
PMID: 36355491
Intracellular pathogens, such as , have been recently shown to induce degradation of p53 during infection, thus impairing the protective response of the host cells. Therefore, p53 reactivation by disruption...
10.
Barravecchia I, Barresi E, Russo C, Scebba F, De Cesari C, Mignucci V, et al.
Molecules
. 2021 Dec;
26(24).
PMID: 34946600
Molecule interacting with CasL 2 (MICAL2), a cytoskeleton dynamics regulator, are strongly expressed in several human cancer types, especially at the invasive front, in metastasizing cancer cells and in the...